Scientists have developed a test that uses cells from a single donor’s blood to predict whether a new drug will cause a severe reaction in humans.
The test could avert disasters like the 2006 trial of the drug TGN1412, which led to six healthy young men being admitted to intensive care with multiple organ failure. The volunteers receiving TGN1412 experienced a catastrophic inflammatory reaction called a cytokine storm.
Cytokine storm reactions are a particular worry for new biological therapies, or “biologics”, which use biological material such as antibodies. Many blockbuster drugs such as the cancer drugs Herceptin and Avastin are biologics, as are around a third of medicines in the pharmaceutical pipeline. Because these medicines are specific to humans, they can cause severe reactions that don’t materialise in animal studies, so tests on human cells are essential.
However, cytokine storm side effects are hard to predict with tests were just one cell type is used, since they depend on interactions between blood cells and endothelial cells, which form the lining of blood vessels. But because endothelial cells are deep within the body, they are normally only grown from tissue removed in surgery or post mortem, or from umbilical vessels after birth.
Because of this, current tests use endothelial cells taken from vessels of one donor, and white blood cells from a different donor. When cells from two different donors are used, one may have an immune reaction to the other, meaning the system is already primed for inflammation before the drug is added. This can result in the test falsely showing a severe immune reaction to a drug that is safe.
Researchers at Imperial College London got around this problem by isolating stem cells from the blood of a volunteer, and using them to grow endothelial cells in a dish. They then took white blood cells which they added to the donor’s own endothelial cells to recreate the unique conditions found in their blood vessels. When TGN1412 was added to the test tube, the mixture of cells released a cytokine storm, as would happen inside the body.
The new method is better as it only requires blood from one donor and doesn’t mix cells from different people, with the advantage of making a more reliable test.
Professor Jane Mitchell, from the National Heart and Lung Institute at Imperial College London, who led the study, said: “As biological therapies become more mainstream, it’s more likely that drugs being tested on humans for the first time will have unexpected and potentially catastrophic effects. We’ve used adult stem cell technology to develop a laboratory test that could prevent another disaster like the TGN1412 trial.
“Drug companies have the technical capacity to start using this test now, but we’re working on developing an off-the-shelf kit which will make it easy to use on a large scale.”
Dr Daniel Reed, the first author on the study, said: ”A further benefit of this new technology is that personalised therapies can be tested to see how safe and effective they will be for an individual.”
Read more: New test uses human stem cells to identify dangerous side effects of drugs
The Latest on: Personalised therapies
[google_news title=”” keyword=”Personalised therapies” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Personalised therapies
- UK man tests personalised melanoma vaccineon April 26, 2024 at 7:04 pm
A man in England is among the first in the world to receive a personalised vaccine, which scientists hope will protect against skin cancer. Stevenage man Steve Young, 52, is one of many skin cancer ...
- Personalized 'cocktails' of antibiotics, probiotics and prebiotics hold promise in treating IBS, pilot study findson April 26, 2024 at 3:10 pm
Personalized "cocktails" of antibiotics, probiotics and prebiotics hold great promise in the treatment of a common form of irritable bowel syndrome (IBS), according to research presented at the ESCMID ...
- Experts develop immune-enhancing therapies to target tuberculosison April 26, 2024 at 3:10 pm
Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body's own immune system to target tuberculosis, with hopes that they could tackle even the ...
- UK Patients Testing World’s First Personalized mRNA Cancer Vaccine For Melanomaon April 26, 2024 at 1:26 pm
British patients are currently undergoing trials for a groundbreaking mRNA cancer vaccine tailored specifically for melanoma, with potential applications for lung, bladder, and kidney cancers as well.
- U.K. Tests World-First Personalized Skin Cancer Vaccineon April 26, 2024 at 9:08 am
Customized with genetic information from a patient’s own tumor, vaccines like this could one day be used against lung, kidney, bladder and colon cancer.
- World’s 1st skin cancer vaccine enters final trial, offers personalized cureon April 26, 2024 at 8:07 am
Scientists are testing the world's first skin cancer vaccine, which has entered global trial. They aim for personalized treatment.
- British patients test world’s first personalised mRNA jab for melanomaon April 25, 2024 at 8:23 pm
The world’s first personalised mRNA cancer jab for melanoma – which also has the potential to stop lung, bladder and kidney cancer – is being tested in British patients. The “gamechanger” jab, which ...
- British patients test world’s first personalised MRNA cancer jab for melanomaon April 25, 2024 at 8:09 pm
The ‘gamechanger’ jab works by telling the body to hunt down cancer cells and prevent the deadly disease from coming back ...
- British man tests first personalised melanoma vaccineon April 25, 2024 at 7:42 pm
An important trial of the world's first "personalised" mRNA vaccine against the deadliest form of skin cancer - melanoma - is now under way in the UK. Steve Young, 52, from Stevenage, Herts, who had a ...
- New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomeson April 17, 2024 at 5:35 am
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has ...
via Bing News